LINZESS has a well-established safety profile among IBS-C patients1

LINZESS was evaluated in 2 phase 3 placebo-controlled safety trials involving more than 1600 adults with IBS-C

IBS-C LINZESS adverse reactions

IBS-C, irritable bowel syndrome with constipation.

*“Abdominal pain” term includes the preferred terms: abdominal pain, upper abdominal pain, and lower abdominal pain.

Diarrhea was the most commonly reported adverse reaction of LINZESS1

  • In placebo-controlled clinical trials, 2% of the IBS-C patients treated with LINZESS reported severe diarrhea vs less than 1% in patients receiving placebo
  • The majority of reported cases of diarrhea started within the first 2 weeks of LINZESS treatment

The most common adverse reaction is diarrhea, which may appear in the first 2 weeks of treatment1